|
Natco Pharma Limited stated that it is investing US$ 14 million in eGenesis, Inc. through its wholly owned subsidiaries, Natco Pharma (Canada) Inc. for an amount of US$ 9.5 million and Natco Pharma South Africa Proprietary Limited for an amount of US$ 4.5 million, though convertible promissory notes.
Previously in 2024, Natco Pharma Limited had invested US$ 8 million in eGenesis, Inc. through preferred stock. The total investment made by Natco Pharma Limited in eGenesis, Inc. now stands at US$ 22 million.
eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage and transform the treatment of organ failure.
The eGenesis Genome Engineering and Production (EGEN) Platform is the only technology of its kind to comprehensively address cross-species molecular incompatibilities and viral risk via genetic engineering to improve the lives of patients in need of a transplant. eGenesis is advancing development programs for kidney transplant, acute liver failure, and heart transplant.
In March 2024, eGenesis announced the world’s first porcine kidney transplant in a living patient. The transplant was authorized by the US Food & Drug Administration (FDA) under the Expanded Access pathway. It was followed by porcine kidney transplants in additional two patients. The outcomes have been exceptionally positive.
|